Aurinia Pharmaceuticals (AUPH) reported a Q1 earnings Monday of $0.16 per diluted share, swinging from a loss of $0.07 a year earlier.
An analyst polled by FactSet expected EPS of $0.14.
Revenue for the quarter ended March 31 was $62.5 million, compared with $50.3 million a year earlier.
Analysts surveyed by FactSet expected $61.1 million.
For 2025, the company reiterated its total revenue guidance in the range of $250 million to $260 million. Analysts surveyed by FactSet expect $258.5 million.
Shares of the company rose 2.5% in recent premarket activity.
Price: 8.20, Change: +0.20, Percent Change: +2.50
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。